MedTrace Logo

Study of Stapokibart Injection in Adolescent Subjects With Seasonal Allergic Rhinitis (SAR)

NCT07617324 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2026-06-01

No results posted yet for this study

Summary

This study is a multicenter, single-arm, open-label, phase II study to evaluate the safety, pharmacokinetics, and immunogenicity of Stapokibart injection in Adolescent Patients with SAR.

Conditions

  • Seasonal Allergic Rhinitis (SAR)

Interventions

BIOLOGICAL

Stapokibart injection

subcutaneous injection

Sponsors & Collaborators

  • Chengdu Kangnuoxing Biopharma,Inc.

    lead INDUSTRY

Principal Investigators

  • Luo Zhang · Beijing Tongren Hospital, CMU

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
12 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-30
Primary Completion
2026-10-31
Completion
2027-02-28

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07617324 on ClinicalTrials.gov